AngioDynamics, Inc. Stock News

AngioDynamics, Inc. ( ANGO ) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Steven Lichtman - Oppenheimer & Co. Inc., Research Division Presentation Danielle Antalffy UBS Investment Ban...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its NanoKnife System has been selected as one of TIME's 2025 Best Inventions. The annual list celebrates groundbreaking products and te...

AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong performance from Auryon, AlphaVac, AngioVac, and NanoKnife products. Gross margin improved to 55.3%, operating costs are under control, and management expects positive cash flow and raised guidance for FY...

AngioDynamics (ANGO 7.00%) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning.

AngioDynamics, Inc. (NASDAQ:ANGO ) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference Call Participants John Young - Canaccord Genuity Corp., Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Re...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended August 31, 2025. Fiscal Year 2026 ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.